Triple test is applied between 14 and 21 gestational weeks and determine the risk for fetal chromosomal abnormalities combining maternal serum levels of AFP, E3, human chorionic gonadotropin (hCG) and maternal age although it is not diagnostic.10 There is also another benefit of triple test that many adverse pregnancy outcomes such as preeclampsia may be understood with these serum markers. The gene discussed is AFP; the disease is preeclampsia.